Which has better earnings & valuation, ATYR or NKTX?

aTyr Pharma has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 269.38 -$74.12M -$0.73 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is ATYR or NKTX more profitable?

Nkarta's return on equity of -30.90% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Nkarta N/A -30.90% -24.20%

Does the media refer more to ATYR or NKTX?

In the previous week, aTyr Pharma had 3 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Nkarta. Nkarta's average media sentiment score of 1.87 beat aTyr Pharma's score of 0.68 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, ALEC or ATYR?

aTyr Pharma has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 8.04 -$142.93M -$1.19 N/A aTyr Pharma $190K 269.38 -$74.12M -$0.73 N/A

Is ALEC or ATYR more profitable?

aTyr Pharma has a net margin of 0.00% compared to Alector's net margin of -680.83%. aTyr Pharma's return on equity of -100.14% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -680.83% -295.17% -40.95% aTyr Pharma N/A -100.14% -73.55%

Does the media refer more to ALEC or ATYR?

In the previous week, aTyr Pharma had 3 more articles in the media than Alector. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Alector. aTyr Pharma's average media sentiment score of 0.68 beat Alector's score of 0.11 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VYGR or ATYR?

In the previous week, aTyr Pharma had 3 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.81 beat aTyr Pharma's score of 0.68 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TARA or ATYR more profitable?

Protara Therapeutics' return on equity of -38.70% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% aTyr Pharma N/A -100.14% -73.55%

Does the media prefer TARA or ATYR?

In the previous week, aTyr Pharma had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.23 beat aTyr Pharma's score of 0.68 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

aTyr Pharma (ATYR) Competitors

$0.52 +0.04 (+7.41%)

As of 10:40 AM Eastern

Compare

ATYR vs. NKTX, ALEC, VYGR, TARA, and CHRS

Should you buy aTyr Pharma stock or one of its competitors? MarketBeat compares aTyr Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with aTyr Pharma include Nkarta (NKTX), Alector (ALEC), Voyager Therapeutics (VYGR), Protara Therapeutics (TARA), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry.

How does aTyr Pharma compare to Nkarta?

aTyr Pharma (NASDAQ:ATYR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

aTyr Pharma presently has a consensus target price of $17.00, suggesting a potential upside of 3,156.70%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 311.09%. Given aTyr Pharma's higher probable upside, research analysts plainly believe aTyr Pharma is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

aTyr Pharma has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	269.38	-$74.12M	-$0.73	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, aTyr Pharma had 3 more articles in the media than Nkarta. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Nkarta. Nkarta's average media sentiment score of 1.87 beat aTyr Pharma's score of 0.68 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

aTyr Pharma has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Nkarta's return on equity of -30.90% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Nkarta	N/A	-30.90%	-24.20%

Summary

Nkarta beats aTyr Pharma on 8 of the 14 factors compared between the two stocks.

How does aTyr Pharma compare to Alector?

Alector (NASDAQ:ALEC) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Alector currently has a consensus price target of $3.63, indicating a potential upside of 137.86%. aTyr Pharma has a consensus price target of $17.00, indicating a potential upside of 3,156.70%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

aTyr Pharma has a net margin of 0.00% compared to Alector's net margin of -680.83%. aTyr Pharma's return on equity of -100.14% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
aTyr Pharma	N/A	-100.14%	-73.55%

85.8% of Alector shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, aTyr Pharma had 3 more articles in the media than Alector. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Alector. aTyr Pharma's average media sentiment score of 0.68 beat Alector's score of 0.11 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

aTyr Pharma has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	8.04	-$142.93M	-$1.19	N/A
aTyr Pharma	$190K	269.38	-$74.12M	-$0.73	N/A

Summary

aTyr Pharma beats Alector on 11 of the 17 factors compared between the two stocks.

How does aTyr Pharma compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, aTyr Pharma had 3 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.81 beat aTyr Pharma's score of 0.68 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 408.32%. aTyr Pharma has a consensus price target of $17.00, suggesting a potential upside of 3,156.70%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Voyager Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

aTyr Pharma has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
aTyr Pharma	N/A	-100.14%	-73.55%

aTyr Pharma has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.86	-$119.72M	-$1.97	N/A
aTyr Pharma	$190K	269.38	-$74.12M	-$0.73	N/A

Summary

Voyager Therapeutics and aTyr Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Protara Therapeutics currently has a consensus price target of $26.25, indicating a potential upside of 541.03%. aTyr Pharma has a consensus price target of $17.00, indicating a potential upside of 3,156.70%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Protara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Protara Therapeutics has higher earnings, but lower revenue than aTyr Pharma. Protara Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
aTyr Pharma	$190K	269.38	-$74.12M	-$0.73	N/A

Protara Therapeutics' return on equity of -38.70% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
aTyr Pharma	N/A	-100.14%	-73.55%

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, aTyr Pharma had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 7 mentions for aTyr Pharma and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.23 beat aTyr Pharma's score of 0.68 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protara Therapeutics beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Coherus Oncology?

aTyr Pharma (NASDAQ:ATYR) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Coherus Oncology has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	269.38	-$74.12M	-$0.73	N/A
Coherus Oncology	$42.17M	5.32	$168.02M	$1.67	0.87

aTyr Pharma has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

aTyr Pharma presently has a consensus target price of $17.00, indicating a potential upside of 3,156.70%. Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 495.65%. Given aTyr Pharma's higher possible upside, equities research analysts plainly believe aTyr Pharma is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has a net margin of 397.30% compared to aTyr Pharma's net margin of 0.00%. aTyr Pharma's return on equity of -100.14% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Coherus Oncology	397.30%	-198.90%	-46.65%

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, aTyr Pharma had 6 more articles in the media than Coherus Oncology. MarketBeat recorded 7 mentions for aTyr Pharma and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.28 beat aTyr Pharma's score of 0.68 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
aTyr Pharma	Positive
Coherus Oncology	Positive

Summary

Coherus Oncology beats aTyr Pharma on 12 of the 17 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$51.18M	$3.63B	$6.74B	$12.60B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.72	21.10	26.92	24.44
Price / Sales	269.38	310.25	519.79	92.02
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	0.76	8.50	10.79	6.34
Net Income	-$74.12M	$23.83M	$3.59B	$331.02M
7 Day Performance	-18.83%	-3.00%	-1.53%	0.37%
1 Month Performance	17.75%	5.61%	2.73%	-0.58%
1 Year Performance	-90.73%	51.57%	28.33%	21.01%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	3.4943 of 5 stars	$0.52 +7.4%	$17.00 +3,156.7%	-91.2%	$51.18M	$190K	N/A	53	News Coverage Analyst Upgrade Gap Up High Trading Volume
NKTX Nkarta	4.0953 of 5 stars	$3.30 +2.5%	$10.75 +225.8%	+40.2%	$230.38M	N/A	N/A	140	News Coverage Positive News
ALEC Alector	2.2427 of 5 stars	$1.94 -5.8%	$3.63 +86.9%	-16.8%	$228.71M	$21.05M	N/A	270
VYGR Voyager Therapeutics	3.3449 of 5 stars	$3.62 -4.2%	$16.50 +355.8%	-7.9%	$228.39M	$40.37M	N/A	100	Analyst Forecast
TARA Protara Therapeutics	3.1029 of 5 stars	$4.08 +0.5%	$26.25 +543.4%	+29.4%	$228.19M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. NKTX, ALEC, VYGR, TARA, and CHRS

How does aTyr Pharma compare to Nkarta?

Summary

How does aTyr Pharma compare to Alector?

Summary

How does aTyr Pharma compare to Voyager Therapeutics?

Summary

How does aTyr Pharma compare to Protara Therapeutics?

Summary

How does aTyr Pharma compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. NKTX, ALEC, VYGR, TARA, and CHRS

How does aTyr Pharma compare to Nkarta?

Do analysts rate ATYR or NKTX?

Which has better earnings & valuation, ATYR or NKTX?

Does the media refer more to ATYR or NKTX?

Do insiders and institutionals hold more shares of ATYR or NKTX?

Which has more risk & volatility, ATYR or NKTX?

Is ATYR or NKTX more profitable?

Summary

How does aTyr Pharma compare to Alector?

Do analysts prefer ALEC or ATYR?

Is ALEC or ATYR more profitable?

Do institutionals and insiders believe in ALEC or ATYR?

Does the media refer more to ALEC or ATYR?

Which has more risk & volatility, ALEC or ATYR?

Which has higher earnings & valuation, ALEC or ATYR?

Summary

How does aTyr Pharma compare to Voyager Therapeutics?

Does the media prefer VYGR or ATYR?

Do analysts rate VYGR or ATYR?

Do institutionals and insiders hold more shares of VYGR or ATYR?

Which has more volatility and risk, VYGR or ATYR?

Is VYGR or ATYR more profitable?

Which has stronger valuation & earnings, VYGR or ATYR?

Summary

How does aTyr Pharma compare to Protara Therapeutics?

Do analysts rate TARA or ATYR?

Which has more volatility & risk, TARA or ATYR?

Which has higher valuation & earnings, TARA or ATYR?

Is TARA or ATYR more profitable?

Do insiders & institutionals believe in TARA or ATYR?

Does the media prefer TARA or ATYR?

Summary

How does aTyr Pharma compare to Coherus Oncology?

Which has preferable earnings and valuation, ATYR or CHRS?

Which has more volatility and risk, ATYR or CHRS?

Do analysts rate ATYR or CHRS?

Is ATYR or CHRS more profitable?

Do institutionals and insiders believe in ATYR or CHRS?

Does the media prefer ATYR or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools